RxDoctor Payments Data

Pedro Lucero, MD

Pulmonary Disease · Tamc, HINPI 1942291950

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $256 and has fallen 66.5% since, to $86 in 2022. That places this record below the midpoint for pulmonary disease clinicians in HI, where the typical reported total is $1,248.

$589in general payments, 2019–2025

Across 25 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$128
  • AstraZeneca$101
  • EKOS Corporation$98
  • Philips North America LLC$68
  • Mylan Specialty L.p.$42
  • United Therapeutics Corporation$26
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$589 in reported general payments places this provider in the 40th percentile of 44 pulmonary disease providers in Hawaii.

See all pulmonary disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$5,044
Medicare patients
19
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Tamc

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →